How many people on Tysabri experience a waning effect as they approach their next dose? How much does this effect impact their symptoms and quality of life?
More data/experience on ‘wearing off phenomenon’ with Ocrevus treatment. Can next infusion be administered at 5 months instead of 6 months to avoid this wearing off phenomenon?
Do some MS patients who are/have taken Ocrevus have advancing disability when compared to other medications. In particular gait and mobility issues.
Does combining intermittent fasting (IF) with Ocrevus treatment help in reducing MS fog in people with progressive MS?
For those taking a B-cell depletion medication such as Ocrevus, are they achieving better results in managing their MS symptoms and slowing progression by combining it with an intermittent-fasting (IF) dietary regiment?
Do people with MS on baclofen experience fatigue worse than those who are not on baclofen? Do people with MS on baclofen experience fatigue worse than people using baclofen for non-MS conditions?
Does the effectiveness of the COVID-19 vaccines differ based on duration of treatment with a B-cell depleting drug?
Should people with MS on B-cell depleting therapies be tested for antibodies after being fully vaccinated as part of standard clinical care?
